Skip to Main Content

There’s more money sloshing around in biotech than ever before.

Over the past year, several trends have converged to create a historic financing environment for startups, full of what industry insiders call “dry powder.”


Experts say this kind of environment could be great for the industry as a whole, allowing startups to raise more money and move much faster. But venture capitalists also told STAT that increased interest in biopharma companies means competition for investment has become unusually fierce.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!